US2023248730A1PendingUtilityA1
Use of inhibitors of brutons tyrosine kinase (btk)
Est. expiryJun 3, 2030(~3.9 yrs left)· nominal 20-yr term from priority
Inventors:Joseph J. Buggy
A61K 31/519A61K 31/195A61P 29/00A61P 35/00A61K 2300/00A61P 7/00A61P 43/00A61K 31/436A61K 31/454A61K 31/475A61K 31/573A61K 31/606A61K 31/675A61K 31/69A61K 31/704A61K 31/7076A61K 45/06A61K 9/4866A61K 47/12A61K 47/10A61K 9/0019A61K 47/20A61K 47/36A61K 47/14A61K 9/0078A61K 47/38A61K 47/26A61K 31/4184A61K 31/4745A61K 31/7032A61K 39/395C07D 487/04A61K 31/337A61K 31/437A61K 39/3955A61K 31/664A61K 39/39533A61K 9/0014A61K 9/0031A61K 9/0048A61K 9/0056A61K 9/007A61K 9/06A61P 35/02
89
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of inhibiting Bruton's tyrosine kinase (BTK) activity in an individual having a B-cell malignancy comprising:
orally administering to the individual a dose of an irreversible BTK inhibitor; wherein the dose is an oral dose determined to result in at least about a 90% mean steady state occupancy of the BTK active sites in peripheral blood mononuclear cells in a population of individuals having the B-cell malignancy.
2 . The method of claim 1 , wherein the dose is a dose determined to result in about 100% mean steady state occupancy of the BTK active sites in peripheral blood mononuclear cells in a population of individuals having the B-cell malignancy.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.